輝瑞(Pfizer)及其合作伙伴BioNTech公司同意向美國政府額外提供1億劑新冠疫苗。目前,美國正在尋求擴(kuò)大疫苗項(xiàng)目、重振經(jīng)濟(jì)。
12月23日,這兩家公司在一份聲明中表示,協(xié)議達(dá)成之后,其向美國銷售的疫苗總數(shù)將達(dá)到2億劑。輝瑞預(yù)計(jì),將在2021年7月31日前以最快的速度將所有疫苗送到美國負(fù)責(zé)新冠疫苗研制的“曲速行動”(Operation Warp Speed)中心。
世界各國都在尋求疫苗供應(yīng),以期待學(xué)校和企業(yè)能夠重新開放、旅游業(yè)恢復(fù)。除了美國,英國也已經(jīng)開始使用輝瑞的疫苗,同時(shí),歐洲藥品監(jiān)管部門也于12月21日批準(zhǔn)了疫苗的使用。
鑒于制藥商對其他國家的承諾,美國一直在努力擴(kuò)大輝瑞等“先鋒疫苗”的供應(yīng)。本月早些時(shí)候,美國向Moderna額外購買了1億劑疫苗。由此,美國向該公司訂購的疫苗數(shù)量翻了一番,達(dá)到2億劑。
與輝瑞及BioNTech一樣,Moderna的疫苗基于信使RNA新技術(shù)的“兩針療法”,但其不需要像輝瑞疫苗那樣在極端低溫下儲存。
今年7月,美國同意向輝瑞支付19.5億美元,購買1億劑初始疫苗,并保有續(xù)購5億劑的權(quán)利。此次發(fā)布的聲明稱,美國也將為新訂單支付19.5億美元,并向美國民眾免費(fèi)提供疫苗。接種疫苗的費(fèi)用由以下三方支付:私人保險(xiǎn)公司、政府保健計(jì)劃和美國衛(wèi)生與公眾服務(wù)部(Department of Health and Human Services)為未購保險(xiǎn)者制定的項(xiàng)目。
輝瑞與美國政府的磋商
數(shù)周以來,美國政府和輝瑞公司一直在就第二季度再交付1億劑疫苗的相關(guān)事宜進(jìn)行磋商?!扒傩袆印庇?jì)劃的首席科學(xué)顧問蒙塞夫?斯拉維在上周的一次采訪中說,輝瑞公司已經(jīng)要求美國通過《國防生產(chǎn)法案》(Defense Production Act),來幫助其獲得額外的設(shè)備和材料,以達(dá)成生產(chǎn)足夠劑量的目標(biāo)。
此前有報(bào)道稱,今年早些時(shí)候,因?yàn)檩x瑞公司“未承諾交付日期”,政府拒絕了其提出的購買更多藥物的要約。斯拉維表示,使用《國防生產(chǎn)法案》有助于更快地向美國公眾提供更多劑量的疫苗。
斯拉維說,為“曲速行動”計(jì)劃生產(chǎn)疫苗的公司使用的都是同樣的原材料,而美國政府已經(jīng)拿到了制藥公司原材料供應(yīng)的優(yōu)先權(quán),當(dāng)然前提是這些公司同意與政府合作進(jìn)行研究、開發(fā)及生產(chǎn)。
新交易的達(dá)成或?qū)⒏淖兠绹洼x瑞之間的關(guān)系。此前,輝瑞拒絕從“曲速運(yùn)動”計(jì)劃中提錢,為其疫苗研究注資。
斯拉維說,輝瑞“決定拒從美國政府處獲取資源”?!案鶕?jù)法律規(guī)定,如果你要求政府給予你《國防生產(chǎn)法案》相關(guān)支持,政府則可以介入你正在生產(chǎn)的任何東西。”他提到。
重癥病例的治療藥物
在確保購置更多疫苗的同時(shí),美國政府也在尋求加強(qiáng)對新冠肺炎患者的治療。
12月23日,美國政府達(dá)成了一項(xiàng)交易,默沙東公司(Merck)將提供一種實(shí)驗(yàn)性的新冠病毒藥物——該藥物從該公司最近收購的OncoImmune處獲得。默沙東在一份聲明中表示,一旦該藥物獲得美國食品與藥品管理局(Food and Drug Administration)的批準(zhǔn),政府將資助該藥物的開發(fā)、生產(chǎn)和分發(fā)。
根據(jù)聲明,至2021年6月底,默沙東公司將拿到3.56億美元,以用于生產(chǎn)及供應(yīng)6萬至10萬劑藥物。該療法旨在抑制病毒誘導(dǎo)的人體細(xì)胞損傷引發(fā)的炎癥,而這種炎癥是部分并發(fā)癥的誘因。據(jù)悉,該療法預(yù)計(jì)將用于治療重癥新冠患者。(財(cái)富中文網(wǎng))
編譯:楊二一
輝瑞(Pfizer)及其合作伙伴BioNTech公司同意向美國政府額外提供1億劑新冠疫苗。目前,美國正在尋求擴(kuò)大疫苗項(xiàng)目、重振經(jīng)濟(jì)。
12月23日,這兩家公司在一份聲明中表示,協(xié)議達(dá)成之后,其向美國銷售的疫苗總數(shù)將達(dá)到2億劑。輝瑞預(yù)計(jì),將在2021年7月31日前以最快的速度將所有疫苗送到美國負(fù)責(zé)新冠疫苗研制的“曲速行動”(Operation Warp Speed)中心。
世界各國都在尋求疫苗供應(yīng),以期待學(xué)校和企業(yè)能夠重新開放、旅游業(yè)恢復(fù)。除了美國,英國也已經(jīng)開始使用輝瑞的疫苗,同時(shí),歐洲藥品監(jiān)管部門也于12月21日批準(zhǔn)了疫苗的使用。
鑒于制藥商對其他國家的承諾,美國一直在努力擴(kuò)大輝瑞等“先鋒疫苗”的供應(yīng)。本月早些時(shí)候,美國向Moderna額外購買了1億劑疫苗。由此,美國向該公司訂購的疫苗數(shù)量翻了一番,達(dá)到2億劑。
與輝瑞及BioNTech一樣,Moderna的疫苗基于信使RNA新技術(shù)的“兩針療法”,但其不需要像輝瑞疫苗那樣在極端低溫下儲存。
今年7月,美國同意向輝瑞支付19.5億美元,購買1億劑初始疫苗,并保有續(xù)購5億劑的權(quán)利。此次發(fā)布的聲明稱,美國也將為新訂單支付19.5億美元,并向美國民眾免費(fèi)提供疫苗。接種疫苗的費(fèi)用由以下三方支付:私人保險(xiǎn)公司、政府保健計(jì)劃和美國衛(wèi)生與公眾服務(wù)部(Department of Health and Human Services)為未購保險(xiǎn)者制定的項(xiàng)目。
輝瑞與美國政府的磋商
數(shù)周以來,美國政府和輝瑞公司一直在就第二季度再交付1億劑疫苗的相關(guān)事宜進(jìn)行磋商。“曲速行動”計(jì)劃的首席科學(xué)顧問蒙塞夫?斯拉維在上周的一次采訪中說,輝瑞公司已經(jīng)要求美國通過《國防生產(chǎn)法案》(Defense Production Act),來幫助其獲得額外的設(shè)備和材料,以達(dá)成生產(chǎn)足夠劑量的目標(biāo)。
此前有報(bào)道稱,今年早些時(shí)候,因?yàn)檩x瑞公司“未承諾交付日期”,政府拒絕了其提出的購買更多藥物的要約。斯拉維表示,使用《國防生產(chǎn)法案》有助于更快地向美國公眾提供更多劑量的疫苗。
斯拉維說,為“曲速行動”計(jì)劃生產(chǎn)疫苗的公司使用的都是同樣的原材料,而美國政府已經(jīng)拿到了制藥公司原材料供應(yīng)的優(yōu)先權(quán),當(dāng)然前提是這些公司同意與政府合作進(jìn)行研究、開發(fā)及生產(chǎn)。
新交易的達(dá)成或?qū)⒏淖兠绹洼x瑞之間的關(guān)系。此前,輝瑞拒絕從“曲速運(yùn)動”計(jì)劃中提錢,為其疫苗研究注資。
斯拉維說,輝瑞“決定拒從美國政府處獲取資源”。“根據(jù)法律規(guī)定,如果你要求政府給予你《國防生產(chǎn)法案》相關(guān)支持,政府則可以介入你正在生產(chǎn)的任何東西?!彼岬?。
重癥病例的治療藥物
在確保購置更多疫苗的同時(shí),美國政府也在尋求加強(qiáng)對新冠肺炎患者的治療。
12月23日,美國政府達(dá)成了一項(xiàng)交易,默沙東公司(Merck)將提供一種實(shí)驗(yàn)性的新冠病毒藥物——該藥物從該公司最近收購的OncoImmune處獲得。默沙東在一份聲明中表示,一旦該藥物獲得美國食品與藥品管理局(Food and Drug Administration)的批準(zhǔn),政府將資助該藥物的開發(fā)、生產(chǎn)和分發(fā)。
根據(jù)聲明,至2021年6月底,默沙東公司將拿到3.56億美元,以用于生產(chǎn)及供應(yīng)6萬至10萬劑藥物。該療法旨在抑制病毒誘導(dǎo)的人體細(xì)胞損傷引發(fā)的炎癥,而這種炎癥是部分并發(fā)癥的誘因。據(jù)悉,該療法預(yù)計(jì)將用于治療重癥新冠患者。(財(cái)富中文網(wǎng))
編譯:楊二一
Pfizer and partner BioNTech agreed to supply an additional 100 million doses of their COVID-19 vaccine to the U.S., as the country seeks to widen its immunization program and revive its economy.
The agreement brings the total number of doses to be delivered to the U.S. to 200 million, the companies said on December 23 in a statement. The drugmaker expects to deliver all the doses to U.S. vaccine and drug accelerator Operation Warp Speed by July 31.
Countries around the world are seeking supplies of vaccine they hope will allow the reopening of schools and businesses and the resumption of travel. The U.K. has also begun administering doses of the Pfizer-BioNTech shot, and European drug authorities cleared it for use on December 21.
The U.S. has been working to expand supplies of the front-runner vaccine, in light of the drugmakers’ commitments to other countries. Earlier this month, the U.S. exercised an option to buy 100 million additional vaccine doses from Moderna, doubling the number it has on order from that company to 200 million.
Like Pfizer and BioNTech’s vaccine, Moderna’s is a two-shot regimen based on new technology known as messenger RNA, but it doesn’t have to be stored at the same ultracold temperatures as the Pfizer-BioNTech shot.
In July, the U.S. had agreed to pay $1.95 billion for an initial 100 million doses from Pfizer, with an option to buy 500 million more. The U.S. will also pay $1.95 billion for the new order, according to the statement, and will provide the vaccine to Americans for free. The cost of administering the vaccines is being paid for by private insurance, government health-care programs and a Department of Health and Human Services program for the uninsured.
U.S.-Pfizer negotiations
The U.S. and Pfizer had been in talks about delivery of another 100 million doses within the second quarter for weeks. Moncef Slaoui, the chief scientific adviser to Operation Warp Speed, said in an interview last week that Pfizer had asked the U.S. to use the Defense Production Act to help the drugmaker secure additional equipment and materials to meet that objective.
The deal follows reports that the government declined an offer to buy more doses earlier this year after Pfizer wouldn’t commit to a delivery date. Using the Defense Production Act could help get more doses to the American public faster, according to Slaoui.
The companies making vaccines for Operation Warp Speed use the same materials, Slaoui said, and the U.S. has been able to get priority access to supplies for drug companies that agreed to work with the government on research, development and manufacturing, he said.
The new deal could alter the dynamics between the U.S. government and Pfizer, which declined to take money from Operation Warp Speed to fund its vaccine research.
Pfizer “decided they didn’t want to take resources from the U.S. government,” Slaoui said. “If you ask the government to give you the Defense Production Act support, the government has, by definition under law, the ability to reach into whatever you’re manufacturing.”
Drug for deadliest cases
At the same time that the government is securing access to more vaccines, it is also looking to shore up the treatments it has available to people who fall ill with COVID-19.
The U.S. agreed to a deal on December 23 in which Merck will supply an experimental COVID drug that the company gained in its recent purchase of OncoImmune. The government will fund the development, production and distribution of the drug once it is cleared for use by the Food and Drug Administration, Merck said in a statement.
Merck will receive about $356 million for manufacturing and supply of 60,000 to 100,000 doses through the end of June, according to the statement. The therapy is designed to tamp down inflammation caused by virus-induced damage to human cells, an underlying cause of some complications, and is expected to be used for treatment of severely ill Covid patients.